Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

AURA Income Before Tax

Profit after all operating and non-operating items but before income tax.

Aura Biosciences, Inc.NASDAQ: AURA

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$33.67M, compared with -$27.47M a year earlier. Trailing-twelve-month income before tax was -$112.29M.

Context

  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$33.67M or moves back toward the trailing-twelve-month quarterly average of -$28.07M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$33.67M-31.8% QoQ
Last fiscal yearDec 2025
-$106.08M-22.2% YoY
LTMMar 2026
-$112.29M-18.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.6%——
1 year-22.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(106.08M) USD
Year-over-year change
-22.2%

Income Before Tax vs competitors

How AURA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -18.7% is the 3rd highest of 11, against a peer median of -37.2%.
AURA Competitors
Income Before Tax for AURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$62.51M USD-395.9%—18764.2%
AKTSAktis Oncology, Inc.FY2025-$63.73M USD-44.9%—980.9%
MGNXMacroGenics, Inc.LTM Mar 2026-$71.03M USD-29.5%—45.2%
OCGNOcugen, Inc.LTM Mar 2026-$71.67M USD-24.7%—1605.2%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.53M USD-68.1%——
OCSOculis Holding AGLTM Mar 2026-CHF 95.35M CHF+7.5%—18919.2%
AURAAura Biosciences, Inc.LTM Mar 2026-$112.29M USD-18.7%——
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$115.81M USD-519.4%——
BCYCBicycle Therapeutics plcLTM Mar 2026-$217.62M USD-4.3%—342.7%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$271.37M USD-85.0%—3563.6%
IMNMImmunome, Inc.LTM Sep 2026-$282.65M USD-26.9%——
Peer median (excluding AURA) —-37.2%—1605.2%

Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue001.3M00
Gross Profit00(1.3M)00
Gross Margin—————
Research & Development25.16M42.24M63.94M73.3M90.3M
Selling, General & Admin10.09M18.06M19.76M22.81M22.49M
Operating Expenses35.25M60.3M83.7M96.12M112.79M
Depreciation & Amortization831K1.18M1.3M1.22M1.13M
EBITDA(34.41M)(57.59M)(74.98M)(85.58M)(104.95M)
EBITDA Margin—————
Operating Income(35.25M)(60.3M)(84.99M)(96.12M)(112.79M)
Operating Margin—————
Interest Income13K1.86M8.59M9.43M6.63M
Interest Expense13K0000
Other Income / Expenses(1K)1.53M8.72M9.31M6.71M
Income Before Tax(35.25M)(58.76M)(76.27M)(86.81M)(106.08M)
Pre-Tax Margin—————
Income Tax Expense00137K112K108K
Net Income(35.25M)(58.76M)(76.41M)(86.92M)(106.19M)
Net Margin—————
EPS (Basic)(1.58)(1.96)(1.93)(1.75)(1.76)
EPS (Diluted)(1.58)(1.96)(1.93)(1.75)(1.76)
Weighted Avg Shares29.21M29.94M39.62M49.65M60.34M
Weighted Avg Shares (Diluted)29.21M29.94M39.62M49.65M60.34M

Aura Biosciences, Inc.

NASDAQ:AURA

Intrinsic Alpha fair value

Locked

Current Price

$7.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.